Comparative Pharmacology
Head-to-head clinical analysis: ASMANEX HFA versus FERNISOLONE P.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASMANEX HFA versus FERNISOLONE P.
ASMANEX HFA vs FERNISOLONE-P
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mometasone furoate is a corticosteroid that exerts anti-inflammatory effects by inhibiting multiple inflammatory cell types and mediators, including eosinophils, mast cells, macrophages, and lymphocytes, and reducing the release of pro-inflammatory cytokines and chemokines.
FERNISOLONE-P is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators like prostaglandins and leukotrienes.
2 inhalations (100 mcg each) twice daily orally, maximum 400 mcg/day.
5-60 mg orally once daily or in divided doses; intravenous, intramuscular, or intra-articular administration per specific indication.
None Documented
None Documented
The terminal elimination half-life of mometasone furoate following inhalation is approximately 25 hours (range 15–40 hours), reflecting slow absorption from the lungs and prolonged systemic clearance.
3.5 hours; in renal impairment (CrCl <30 mL/min) may extend to 8-10 hours, requiring dose adjustment
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver. Excretion is primarily via feces (approximately 74%) and urine (approximately 8%) as metabolites. Biliary excretion contributes to fecal elimination.
Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Corticosteroid, Inhaled
Corticosteroid